查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138411

病毒载体和质粒 DNA 製造的全球市场 - 2022-2029

Global Viral Vector and Plasmid DNA Manufacturing Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球病毒载体和质粒 DNA 製造市场的增长受到多种因素的推动，例如 DNA 疫苗开发、基因治疗、免疫治疗等对病毒载体和质粒 DNA 製造的需求增加。

预计在预测期内，对基因治疗和免疫治疗的需求不断增长将推动全球病毒载体和质粒 DNA 製造市场。

该市场的驱动力是对用于开发 DNA 疫苗、基因疗法、免疫疗法等的病毒载体和质粒 DNA 生产的需求不断增加。病毒载体和质粒DNA因其转染效率高、基因转移效率高、基因表达稳定等优点而不断发展壮大。验证病毒载体和质粒 DNA 有效性和安全性的临床试验正在增加。

病毒载体和质粒 DNA 的合同製造企业数量正在增加。例如，2019 年 12 月，Helicsmith Co., Ltd. 和 Genopis Inc. 开始了质粒 DNA 製造的合同製造业务。我们将通过可行性运行安装额外的小型反应器（60-300L、6-30L）并开始小批量生产服务。 Genopis 拥有正确的技术和质量体系。

多家公司已与多家组织合作生产病毒载体和质粒 DNA。例如，2020 年 6 月，Oxford Biomedica plc 与为提供英国首个战略性疫苗开发和先进製造能力而成立的非营利组织疫苗製造与创新中心 (VMIC) 签署了合作协议。这项为期五年的协议将使两家公司能够生产基于病毒载体的疫苗，并有助于英国国内在疫苗製造这一专业领域的产能快速增长。根据协议条款，VMIC 将向 Oxford Biomedica 提供製造设备，并在 Oxford Biomedica 位于英国牛津的新 7,800 平方米商业生产设施 Oxbox 内建立两个新的 GMP 製造室。

与载体和质粒治疗相关的诱变风险可能会阻碍市场增长

基因工程病毒载体和质粒 DNA 用于多种基因和免疫疗法。这些转基因载体和质粒存在插入诱变风险，可能会抑制市场增长，基因治疗的高成本也可能限制市场增长。

行业分析

全球病毒载体和质粒 DNA 製造市场根据波特五力、监管分析、供应链分析和价格分析等各种行业因素对市场进行了深入分析。

全球病毒载体和质粒 DNA 製造市场报告提供了大约 45 多个市场数据表、40 多个图表和 180 页的组成。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 对基因疗法和免疫疗法的需求不断增长
      • 癌症和遗传疾病等疾病的发病率增加
    • 限制因素
      • 致突变风险
      • 基因治疗费用高
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 监管分析
  • 供应链分析
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结
  • 其他

第 7 章按产品类型

  • 质粒 DNA
  • 病毒载体
    • 逆转录病毒载体
    • 腺病毒载体
    • 慢病毒载体
    • 腺相关病毒载体
    • 其他
  • 非病毒载体

第 8 章. 按应用程序

  • 癌症
  • 遗传性疾病
  • 感染
  • 其他疾病

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 按产品类型进行基准测试
  • 值得关注的重点公司列表

第 11 章公司简介

  • Brammer Bio（Thermo Fisher Scientific Inc.）
    • 公司简介
    • 按产品类型划分的产品组合和内容
    • 主要亮点
    • 财务摘要
  • Cobra Biologics
  • Cell and Gene Therapy Catapult
  • FinVector Vision Therapies
  • Fujifilm Diosynth Biotechnologies
  • MassBiologics
  • SIRION Biotech
  • Merck KGaA Inc.
  • Thermo Fisher Scientific
  • Uniqure NV

第12章 全球病毒载体和质粒 DNA 製造市场-DataM

简介目录
Product Code: DMBT2571

Market Overview

Viral Vector and Plasmid DNA Manufacturing Market size was valued US$ 2.85 billion in 2021 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of 14.2% during the forecast period (2022-2029).

The viral vector is referred to as the tool for delivering genetic material into cells. The modified viral vector is used as a viral vector in gene therapy. Plasmid DNA is a bacterial smaller, circular, and extrachromosomal DNA used in different molecular genetic research such as gene therapy, gene transfer, and recombinant DNA technology due to its self-replication property. A gene of interest is transferred into the target cell for studying the function or expression of a gene.

Market Dynamics

The global viral vector and plasmid DNA manufacturing market growth is driven by several factors such as increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others.

Increasing demand for gene therapy and immunotherapy is expected to drive the global viral vector and plasmid DNA manufacturing market during the forecast period.

The market is driven by the increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others. There are growing viral vectors & plasmid DNA due to their advantages such as high transfection efficiency, effective gene delivery, and stable gene expression. There is an increase in the number of clinical studies examining the viral vectors' efficacy and safety and plasmid DNA.

There is an increase in the contract manufacturing business launch for viral vectors and plasmid DNA manufacturing. For instance, in December 2019, Helixmith Co., Ltd. and Genopis launched the contract manufacturing business for plasmid DNA production. The company would establish additional smaller-scale reactors (60-300 L, 6-30 L) with feasibility runs and start a small-volume production service. Genopis is equipped with the right technologies and quality systems.

Several companies are entering into a collaboration with several organizations to manufacture viral vectors and plasmid DNA. For instance, in June 2020, Oxford Biomedica plc entered into a collaboration agreement with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization established to provide the UK's first strategic vaccine development and advanced manufacturing capability. This five-year agreement would involve the organizations working collaboratively to enable the manufacture of viral vector-based vaccines, contributing to a rapid increase in the United Kingdom domestic capacity for this specialized vaccine manufacturing field. Under the terms of the agreement, VMIC would provide manufacturing equipment for Oxford Biomedica to equip two new GMP manufacturing suites within Oxford Biomedica's new 7,800 m2 commercial manufacturing center, Oxbox, located in Oxford, United Kingdom.

Risk of mutagenesis associated with vector or plasmid treatments are likely to hinder the market growth

As genetic engineered viral vector and plasmid DNA are being used in various gene therapy and immunotherapy procedures. There is a risk of insertional mutagenesis associated with these genetic modified vectors and plasmids that can restrain the market growth and the high cost of gene treatments can also limit the growth of market.

Industry Analysis

The global viral vector and plasmid DNA manufacturing market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis, pricing analysis.

Segment Analysis

The viral vector segment is expected to hold the largest market share in global viral vector and plasmid DNA manufacturing market

The global viral vector and plasmid DNA manufacturing market is segmented on the product type the plasmid DNA, viral vector, and non-viral vector. The viral vector segment accounts for the highest market growth due to the increasing penetration of the viral vectors for targeted delivery, efficient transduction, and controlled gene expression. There is an increase in the viral vectors' usage due to their efficiency in delivering genes into the target cells and protecting the new genes from degradation. Different types of viral vectors such as retrovirus, lentivirus, adenovirus, adeno-associated virus, and herpes simplex virus are used for transferring the nucleic acids into the genetic makeup of cells. Out of these viral vectors, adenovirus and retrovirus are widely used worldwide as these viral vectors have the integration ability with large transgenes and easy production at high titers.

Several companies are focusing on expanding the manufacturing facilities for the viral vectors to meet the increasing demand. For instance, in May 2019, Thermo Fisher Scientific Inc. had opened its new $90 million viral vector contract development and manufacturing organization (CDMO) site in Lexington, MA. The 50,000-square-foot facility would support the development, testing, and manufacture of viral vectors essential for advancing gene and cell therapies globally.

Further, the market is also classified based on cancer, genetic disorder, infectious disease, and other diseases. The cancer segment accounts for the highest market share due to the higher usage of the viral vector and plasmid DNA for delivering the anti-cancer genes. Several biotechnology and pharmaceutical companies are examining the viral vectors or plasmid DNA encoding a therapeutic gene, often an immunomodulatory or suicide gene, in the various cancer gene therapy trials. Clinical studies have demonstrated that the injection of plasmid DNA encoding a cytokine gene has a significant antitumor effect. There are increasing research and development activities for gene therapies and other advanced cell therapies to treat various cancers. The increase in the approval of the viral vector and plasmid DNA-based therapies shall stimulate market growth. For instance, the lentiviral vector-based CAR-T cell therapies are approved for treating Acute Lymphoblastic Leukemia (ALL) and large B cell lymphoma.

Geographical Analysis

North America region holds the largest market share in the global viral vector and plasmid DNA manufacturing market

By region, the global viral vector and plasmid DNA manufacturing market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global viral vector and plasmid DNA manufacturing market and is expected to grow at the highest CAGR during the forecasted period due to the increasing number of clinical studies for evaluating the use of the viral vector and plasmid DNA for the treatment of the genetic disorders, cancer, and infectious diseases. The increase in the approval of advanced cell therapies shall stimulate market growth. There is growing research and development activities of gene therapies. Several companies, institutes, associations, and foundations raise the investment and funding to develop gene therapies. The growing initiatives by the Food and Drug Administration (FDA) for improving the regulatory support for cell and gene therapy shall boost the demand for viral vector and plasmid DNA manufacturing.

The Asia Pacific is expected to witness positive market growth due to the growing clinical transformation and industrialization of advanced therapies medicinal products, including gene therapy manufacturing. There is a presence of several companies manufacturing the viral vector and plasmid DNA. Contract manufacturers are providing several services for viral vector and plasmid DNA manufacturing. There is growing adoption of advanced technologies for manufacturing viral vectors and plasmid DNA.

Competitive Landscape

The global viral vector and plasmid DNA manufacturing market is highly competitive with several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Brammer Bio, Cobra Biologics, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc., Thermo Fisher Scientific, and Uniqure NV are the leading market players with significant market share.

The major players enter into collaborations, acquisitions, mergers, and licensing activities to increase their market presence. For instance, in Apr 2022, FUJIFILM Diosynth Biotechnology, a Contract Development Manufacturing Organisation that develops recombinant biopharmaceuticals and viral gene therapy announced its manufacturing agreement with Chimeron Bio, RNA company that develops self-amplifying RNA vaccines and therapies that are developed by their own proprietary ChaESAR RNA delivery platform.

In March 2019, Merck entered into the non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing. The manufacturing of high-quality plasmids and viral vectors would help in the commercialization of cell and gene therapy. This collaboration would help the company accelerate the industrialization and commercialization of cell and gene therapy in China. Merck would provide GenScript with comprehensive products, training, and consulting services covering process design, facility concept design, and quality management system set-up from lab development to large-scale GMP manufacturing.

Key Companies to Watch

Brammer Bio:

Overview: Brammer Bio is a contract development and manufacturing organization (CDMO) that develops and manufactures viral vector and helps biopharmaceutical companies to deliver breakthrough medicines in form of gene modified cell therapies to patients. Founded in 2013 and headquartered in Florida.

Product Portfolio:

Lipofectamine CRISPRMAX Cas9 Transfection Reagent: It is a 1st lipid nanoparticle optimized reagent for transfection use for CRISPR-Cas9 protein delivery. It is a cost effective, high throughput friendly alternate for electroporation.

Key Developments: In May 2019, Thermo Fisher Scientific Inc., company serving science announced acquisition of Brammer Bio, viral vector manufacturing company for gene therapies for around $1.7 billion.

The global viral vector and plasmid DNA manufacturing market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. The growing demand of gene therapy and immunotherapy
      • 4.1.1.2. Increase in the incidence of diseases such as cancer and genetic disorders.
    • 4.1.2. Restraints:
      • 4.1.2.1. Risk of mutagenesis
      • 4.1.2.2. High cost of gene therapy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion
  • 6.7. Others

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Plasmid DNA
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Viral Vector
    • 7.3.1. Retroviral Vectors
    • 7.3.2. Adenoviral Vectors
    • 7.3.3. Lentiviral Vectors
    • 7.3.4. Adeno-Associated Viral Vectors
    • 7.3.5. Others
  • 7.4. Non-Viral Vector

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cancer
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Mn and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Genetic Disorder
  • 8.4. Infectious Disease
  • 8.5. Other Diseases

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Type Benchmarking
  • 10.4. List of Key Companies to Watch

11. Company Profiles

  • 11.1. Brammer Bio (Thermo Fisher Scientific Inc.)
    • 11.1.1. Company Overview
    • 11.1.2. Product Type Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Cobra Biologics
  • 11.3. Cell and Gene Therapy Catapult
  • 11.4. FinVector Vision Therapies
  • 11.5. Fujifilm Diosynth Biotechnologies
  • 11.6. MassBiologics
  • 11.7. SIRION Biotech
  • 11.8. Merck KGaA Inc.
  • 11.9. Thermo Fisher Scientific
  • 11.10. Uniqure NV

LIST NOT EXHAUSTIVE

12. Global Viral Vector and Plasmid DNA Manufacturing Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Usability
  • 12.3. Contact Us